New 'Living Drug' trial offers hope for Tough-to-Treat lupus

NCT ID NCT06892145

First seen Jan 08, 2026 · Last updated Apr 16, 2026 · Updated 14 times

Summary

This is an early-stage trial testing a new cell therapy called MC-1-50 for adults with severe lupus that hasn't responded to standard treatments. Doctors will modify a patient's own immune cells to target and remove harmful B cells, which are thought to drive the disease. The main goals are to see if the treatment is safe, find the best dose, and get an early look at whether it helps control lupus symptoms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)

    RECRUITING

    Hefei, Anhui, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.